NCT04018313View on ClinicalTrials.gov

To Compare the PK and Safety of Omalizumab (CT-P39, EU-approved Xolair, and US-licensed Xolair) in Healthy Subjects

PHASE1CompletedINTERVENTIONAL

Enrollment

176

Participants

Timeline

Start Date

May 28, 2020

Primary Completion Date

March 27, 2021

Study Completion Date

April 30, 2021

Conditions

Healthy

Interventions

BIOLOGICAL

CT-P39

150 mg/mL, Solution for injection in PFS

BIOLOGICAL

EU-approved Xolair

150 mg/mL, Solution for injection in PFS

BIOLOGICAL

CT-P39

150 mg/mL, Solution for injection in PFS

BIOLOGICAL

EU-approved Xolair

150 mg/mL, Solution for injection in PFS

BIOLOGICAL

US-licensed Xolair

150 mg/mL, Solution for injection in PFS

Trial Locations (2)

4006

Phase 1 unit, Herston

5000

Phase 1 unit, Adelaide

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Celltrion

INDUSTRY